To evaluate the clinical effect of cisapride on irritable bowel syndrome based on gastrointestinal motility regulation.

A total of 138 patients with irritable bowel syndrome in Huizhou Central People’s Hospital were randomly selected from June 2016 to May 2017. On the basis of conventional the treatment, according to the dose of cisapride, the patients were divided into low dose group of 15 mg/d, medium dose group of 30 mg/d and high dose group of 60 mg/d. After 8 weeks of treatment, the total clinical efficacy, clinical symptom scores and adverse reactions of each group were compared after treatment.

At the end of the treatment, the total clinical effective rate of the high-dose group was 91.3%, which was significantly higher than that in the medium dose group and low dose group, there were significant differences among the groups (F=11.65, P<0.05). The clinical symptom scores presented dose dependent trend, with the increase of dose, the clinical symptom scores of postprandial abdominal distension, nausea, vomiting, abnormal defecation, endless defecate sense and mental symptoms before and after treatment were decreased, and declined most in high dose group, there were significant differences among the groups (P<0.05). However, there was no significant difference among the three groups in abdominal pain or psychiatric symptoms(P>0.05). The incidence of adverse reactions in the high dose group was 13.04%, and there was no significant difference between the other two groups(P>0.05).

Cisapride has a dose dependent manner to regulate gastrointestinal dynamics for irritable bowel syndrome, which can regulate the gastrointestinal dynamics, relieve the clinical symptoms, and without increase the adverse reactions. It provides a good basis for clinical application.

Gastrointestinal motility; Cisapride; Lrritable bowel syndrome